| 2581 |
|
Surgery for Valvular Heart Disease - Regression of Left Ventricular Hypertrophy After Surgical Therapy for Aortic Stenosis Is Associated With Changes in Extracellular Matrix Gene Expression/
|
Walther, Thomas
|
American Heart Association, etc.]
|
2001
|
|
|
|
| 2582 |
|
Surgery for Valvular Heart Disease - Surgical Management of Left-Sided Carcinoid Heart Disease/
|
Connolly, Heidi M
|
American Heart Association, etc.]
|
2001
|
|
|
|
| 2583 |
|
Surgery for Valvular Heart Disease - Ten-Year Experience of Chordal Replacement With Expanded Polytetrafluoroethylene in Mitral Valve Repair/
|
Kobayashi, Junjiro
|
American Heart Association, etc.]
|
2000
|
|
|
|
| 2584 |
|
Surgery for Valvular Heart Disease - Ten-Year Experience of Chordal Replacement With Expanded Polytetrafluoroethylene in Mitral Valve Repair/
|
Kobayashi, Junjiro
|
American Heart Association, etc.]
|
2000
|
|
|
|
| 2585 |
|
Surgery for Valvular Heart Disease - Time Course of Aortic Valve Function and Root Dimensions After Subcoronary Ross Procedure for Bicuspid Versus Tricuspid Aortic Valve Disease/
|
Schmidtke, Claudia
|
American Heart Association, etc.]
|
2001
|
|
|
|
| 2586 |
|
Surgery for Valvular Heart Disease - Tissue Engineering of Pulmonary Heart Valves on Allogenic Acellular Matrix Conduits: In Vivo Restoration of Valve Tissue/
|
Steinhoff, Gustav
|
American Heart Association, etc.]
|
2000
|
|
|
|
| 2587 |
|
Surgery for Valvular Heart Disease - Tissue Engineering of Pulmonary Heart Valves on Allogenic Acellular Matrix Conduits: In Vivo Restoration of Valve Tissue/
|
Steinhoff, Gustav
|
American Heart Association, etc.]
|
2000
|
|
|
|
| 2588 |
|
Surgery for Valvular Heart Disease - Very Long-Term Results (More Than 20 Years) of Valve Repair With Carpentier's Techniques in Nonrheumatic Mitral Valve Insufficiency/
|
Braunberger, E
|
American Heart Association, etc.]
|
2001
|
|
|
|
| 2589 |
|
Surgery for Valvular Heart Disease - Very Long-Term Survival and Durability of Mitral Valve Repair for Mitral Valve Prolapse/
|
Mohty, Dania
|
American Heart Association, etc.]
|
2001
|
|
|
|
| 2590 |
|
Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure: Results From the Valsartan Heart Failure Trial/
|
Cohn, J. N
|
American Heart Association, etc.]
|
2003
|
|
|
|
| 2591 |
|
Synergistic Effect of Persistent Chlamydia pneumoniae Infection, Autoimmunity, and Inflammation on Coronary Risk/
|
Huittinen, T
|
American Heart Association, etc.]
|
2003
|
|
|
|
| 2592 |
|
Synergistic Effect of Urotensin II With Mildly Oxidized LDL on DNA Synthesis in Vascular Smooth Muscle Cells/
|
Watanabe, Takuya
|
American Heart Association, etc.]
|
2001
|
|
|
|
| 2593 |
|
Systemic Delivery of Bone Marrow-Derived Mesenchymal Stem Cells to the Infarcted Myocardium: Feasibility, Cell Migration, and Body Distribution/
|
Barbash, I. M
|
American Heart Association, etc.]
|
2003
|
|
|
|
| 2594 |
|
Targeted In Vivo Labeling of Receptors for Vascular Endothelial Growth Factor: Approach to Identification of Ischemic Tissue/
|
Lu, E
|
American Heart Association, etc.]
|
2003
|
|
|
|
| 2595 |
|
Targeted Overexpression of Transmembrane Tumor Necrosis Factor Provokes a Concentric Cardiac Hypertrophic Phenotype/
|
Dibbs, Z. I
|
American Heart Association, etc.]
|
2003
|
|
|
|
| 2596 |
|
Targeting of Mitogen-Activated Protein Kinases and Phosphatidylinositol 3 Kinase Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Angiogenesis/
|
Sengupta, S
|
American Heart Association, etc.]
|
2003
|
|
|
|
| 2597 |
|
Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study/
|
Wang, T. J
|
American Heart Association, etc.]
|
2003
|
|
|
|
| 2598 |
|
Temporal Trends in Sudden Cardiac Arrest: A 25-Year Emergency Medical Services Perspective/
|
Rea, T. D
|
American Heart Association, etc.]
|
2003
|
|
|
|
| 2599 |
|
The cover figure is from the article in this issue by Kawamoto et al. Figure 1: Representative findings of fluorescence microscopy 7 days after EPC transplantation (a, X100; b and c, X400) and immunohistochemistry using antibodies against human-specific ECs (d, ulex europaeus lectin type 1 staining; e, human CD31 staining; both X400) in ischemic myocardium of nude rats treated with ex vivo expanded human EPCs. a through c, Red fluorescence indicates DiI-labeled human EPCs; green fluorescence shows Bandeiraea simplicifolia lectin 1-positive rat ECs. d through e, Transplanted human EPCs differentiated to mature ECs (arrows) at sites of neovascularization./
|
|
American Heart Association, etc.]
|
2001
|
|
|
|
| 2600 |
|
The cover figure is from the article in this issue by Weiss et al. Figure 1: Representative unstained en face dissections of descending thoracoabdominal aorta from apoE-deficient animals after 8 weeks of treatment. Ang II indicates subcutaneous angiotensin II infusion (0.7 mg . kg-1 . d-1). See page 448./
|
|
American Heart Association, etc.]
|
2001
|
|
|
|
Kereiakes, D. J
(7)
